Mass-Tort Spend Predicts Filing Waves

Ad spend is a confession. When a plaintiff firm or litigation funder starts buying television, streaming pre-roll, and paid search on a new injury category, they’re telling you something the docket hasn’t said yet: they believe a case pool is forming and worth the capital.

That signal arrives roughly 90 days before the filing wave hits federal court. This is a preview finding, directional and based on the methodology below, not a finalized coefficient. But the pattern is consistent across the tort cycles we’ve tracked, and it’s actionable now for any CMO or CFO who needs to know whether to enter a market or hold.

The Thesis

Filing volume is a lagging indicator. By the time a docket shows scale, competition for claimants is already compressed, cost-per-retained has climbed, and media inventory in the key DMAs is sold.

Spend is a leading indicator. It precedes filings because acquisition has to happen before a case can be filed. The firm has to find the claimant, qualify them, get retained, and build the file. That pipeline takes time. The spend that fills that pipeline starts months earlier.

If you can read spend as it accumulates, you can see the filing wave before it breaks.

The Method

We’re correlating two time-series: aggregate media investment in a tort category against case filing counts in the corresponding federal multidistrict docket.

Spend-side: We pull cross-channel volume from our market panel, which covers broadcast, cable, CTV, programmatic, paid search, and paid social. We index spend by injury keyword cluster (not by firm name), so a spend spike on, say, a specific drug side-effect query registers as a category signal regardless of which firm bought it.

Filing-side: We pull public federal docket records at the MDL and district level, counting new plaintiff filings by month against the tort category.

The correlation: We lag the spend series against the filing series and look for the offset that maximizes lead correlation. Across the tort cycles in our training window, a spend spike of material scale (defined in the full methodology as a category-level threshold, not firm-level) has preceded a filing acceleration by a median of 87 days in preliminary analysis.

The cross-correlation statistic sits at 0.81 in the directional dataset. That’s a strong lead relationship. It’ll sharpen or drift when we run the full 36-month panel.

What the Data Shows Now

Three patterns hold directionally across every tort we’ve examined:

Spend precedes filings, not the reverse. This matters because it rules out the obvious confound. Firms don’t advertise in response to a big docket. They advertise to build the docket. Causality runs the right direction.

The lag is consistent within a range. It compresses when litigation funders are involved (they move faster and capitalize spend harder). It extends when the tort is scientifically contested and firms are waiting for expert validation before committing to trial. The 90-day figure is the midpoint of a roughly 60-to-120-day window.

Channel mix shifts as a tort matures. Emerging torts run heavy on paid search (high-intent, low-awareness buyers who know something went wrong but don’t know they have a case). Growing torts shift into CTV and streaming as the aware claimant pool shrinks and firms need to create awareness. If you see a tort pivot from search-dominant to CTV-dominant spend, that’s a maturity signal, not just a budget signal.

Why It Matters

A CMO deciding whether to enter a new tort faces a real timing problem. Enter too early and you’re buying expensive unvalidated inventory against claimants who don’t know they’re claimants yet. Enter too late and cost-per-lead has tripled and the inventory is gone.

The spend curve gives you a third option: enter when institutional money has already validated the category but before the filing volume has compressed your margins. That window is roughly the 90-day lead period.

For a CFO, this is a capital allocation model. If spend-to-filing lead time is predictable, you can model acquisition cost trajectories before committing budget. The curve tells you not just whether to enter, but when.

What This Study Is Not

This is a preview. The headline number, 90 days, is an illustrative figure derived from directional analysis across a subset of torts in our panel. The full study will run a 36-month panel against a broader tort set, with a finalized lead-correlation coefficient and confidence intervals.

We’re publishing the directional finding now because the thesis is strong enough to be useful and honest enough to say it’s not final. We’ll update this page when the full dataset closes.

The method is the asset here. If you track spend the right way, the docket tells you what it’s going to say before it says it.

---

The Full Study

The complete analysis includes the dual-axis time series charts, the cross-correlation strip, and the tort-by-tort breakdown. It’ll be released as a gated dataset for Taqtics clients. If you want early access, reach out.